Comparative Pharmacology

Head-to-head clinical analysis: NALTREXONE versus ZIMHI.

Peer-Reviewed Evidence

Differential Analysis

NALTREXONE vs ZIMHI

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

NALTREXONE

Opioid Antagonist

Category A/B

ZIMHI

Opioid Antagonist

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Naltrexone is a pure opioid antagonist that competitively binds to μ-opioid receptors, blocking the effects of endogenous and exogenous opioids. It also antagonizes κ- and δ-opioid receptors to a lesser extent.

Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.

Clinical Dosing

Oral: 50 mg once daily for opioid dependence; 25 mg initially for first dose to minimize adverse effects. Intramuscular: 380 mg every 4 weeks for alcohol dependence.

5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.

Direct Interaction

None Documented

Half-Life

Naltrexone: 3.9–10.3 hours; active metabolite 6β-naltrexol: 12.9 hours. Context: Trough levels of 6β-naltrexol sustain receptor blockade for 24–48 h.

Other Significant Interactions

Clinical Note

moderate

Methylnaltrexone + Fesoterodine

"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone."

Clinical Note

moderate

Naltrexone + Methadone

"The therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone."

Clinical Note

moderate

Naltrexone + Dabigatran etexilate

"The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone."

Clinical Note

moderate